Pegfilgrastim Biosimilar Market Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2020 to 2026

Published on : Oct-2020 | List of Tables : 16 | List of Figures : 49 | No. of Pages : 170 | Report Code : FACT1494MR |

Global Pegfilgrastim Biosimilar Market Overview

Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.

The COVID-19 pandemic effect has been moderate on the overall pegfilgrastim market. COVID-19 has overall affected the speed of processes in clinical trials, but it’s predicted that, there will not be any near-term effect on approval processes by the regulatory bodies.

Pegfilgrastim Biosimilar Market Insights by Distribution Channel

The distribution channel includes hospital pharmacies, retail pharmacies, and mail-Order pharmacies. Hospital pharmacies have dominated the market, capturing over 50% market share in the global pegfilgrastim biosimilar market. Owing to increasing adoption of chemotherapy for cancer treatment across the globe, hospital pharmacies will be the most adoptive sector in the pegfilgrastim biosimilar market.

Regional Outlook of Pegfilgrastim Biosimilar Market

The pegfilgrastim biosimilar market is segmented into the following regions - North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa. North America is the dominant region that holds over 3/4 of the global pegfilgrastim biosimilar market share. Majority of pegfilgrastim biosimilar developers target North America for their product launches, owing to growing demand for biosimilars in this region.

North America has experienced increasing spending on biologics for cancer and related disease treatment over the past few years. Also, rising prevalence of cancer and advanced healthcare facilities make North America the most attractive region for pegfilgrastim biosimilar market players. The pegfilgrastim biosimilar market in the Asia Pacific region is likely to witness significant growth due to increasing prevalence of cancer coupled with lowering of prices owing to launch of various biosimilars. The adoption of originator pegfilgrastim (Neulasta) in Asia Pacific has remained limited due to higher cost of the product, resulting in limited accessibility.

pegfilgrastim biosimilar market

To understand the regional dynamics of the pegfilgrastim biosimilar market, request a report sample

Pegfilgrastim Biosimilar Market: Key Players

The pegfilgrastim biosimilar market is significantly consolidated and competitive in nature. Many small and large pharmaceutical companies have developed this biosimilar. Key players operating in the market are Coherus Biosciences, Mylan N.V., Biocon, and Novartis AG (Sandoz). These companies have launched pegfilgrastim biosimilars and are bolstered with partnerships and collaborations for expanding their market presence, globally. Other players in the market are Pfizer Inc, Green Cross Corp, Accord healthcare, Intas Pharmaceuticals Ltd, and Zydus Cadila. These players are focused on strategic collaborations & partnerships and investments in research & development for developing novel biosimilar platforms.  

pegfilgrastim biosimilar market tier structure analysis

For a dashboard view of key players operating in the pegfilgrastim biosimilar market, request a expert analyst

The Analyst’s Viewpoint

“Key players should target emerging markets along with developed markets to make the access of affordable biosimilar therapeutics easy for a large patient population, and, in turn, expand their global footprints.”

COVID-19 Impact on Pegfilgrastim Biosimilar market

COVID-19 has affected the pace of clinical trials, eventually leading to delays in the approval process. Delays caused by the COVID-19 pandemic crisis may lead to a backlog of approvals, and eventually delay the launches of 2020. Coherus Biosciences, a key manufacturer of pegfilgrastim biosimilar, mentioned that, the company does not import its active pharmaceutical ingredients (API) for UDENYCA from countries such as China and India, and therefore, its manufacturing did not get impacted by the coronavirus pandemic. The overall effect of the COVID-19 outbreak on the pegfilgrastim biosimilar market has been moderate.

Pegfilgrastim Biosimilar Market: About the Report

Fact.MR published an exclusive forecast report on the pegfilgrastim biosimilar market for 2020 to 2026. The foremost objective of this report on the pegfilgrastim biosimilar market is to pitch spearhead insights on the market scenario, demand generators, and product developments in the pegfilgrastim biosimilar market. Also, the study addresses key dynamics that are expected to diversify the sales and future prominence of pegfilgrastim biosimilars.              

The report on the pegfilgrastim biosimilar market begins with an executive overview, in which, product definition has been provided. The report further proceeds with the taxonomy of the pegfilgrastim biosimilar market, elaborating on key segments. Also, the report outlines visionary insights on the dynamics of the pegfilgrastim biosimilar market, including the drivers, restraints, opportunities, trends, and developments for pegfilgrastim biosimilars. Current product pipeline analysis has also been included in the report, to help readers clearly understand the future product framework map in the pegfilgrastim biosimilar market.

Pegfilgrastim Biosimilar Market – Report Scope

Fact.MR recently published a market study on the global market for pegfilgrastim biosimilars. The study provides detailed assessment of key market dynamics, including the drivers, trends, opportunities, and restraints, as well as detailed information about the pegfilgrastim biosimilar market structure. The market study presents exclusive information about how the pegfilgrastim biosimilar market will grow during the forecast period (2020 to 2026).

Key indicators of market growth, which include year-on-year (Y-o-Y) growth of the market and compounded annual growth rate (CAGR) are explained in Fact.MR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the pegfilgrastim biosimilar market during the forecast period.

The study is relevant for stakeholders in the pegfilgrastim biosimilar market, including manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the pegfilgrastim biosimilar market, investors, industry experts, researchers, and journalists, as well as business researchers, can leverage the information and data presented in Fact.MR’s study.

It also offers actionable insights based on the future trends in the pegfilgrastim biosimilar market. Furthermore, small businesses and new entrants in the pegfilgrastim biosimilar market too can make use of the information presented in this study, based on which, they can make appropriate business decisions to gain momentum in the market.

Key Segments of Pegfilgrastim Biosimilar Market

Fact.MR’s study on the pegfilgrastim biosimilar market offers information divided into two important segments— distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories, for the better understanding of readers.

Distribution Channel

Region

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Key Questions Answered in Fact.MR’s Pegfilgrastim Biosimilar Market Report

  • Which regions will continue to remain the most profitable regional markets for pegfilgrastim biosimilar market players?
  • Which factors will induce a change in the demand for pegfilgrastim biosimilars during the assessment period?
  • How will changing trends impact the pegfilgrastim biosimilar market?
  • What effect will the COVID-19 pandemic have on the global pegfilgrastim biosimilar Market
  • How can market players capture the low-hanging opportunities in the pegfilgrastim biosimilar market in developed regions?
  • Which companies are leading the pegfilgrastim biosimilar market?
  • What are the winning strategies of stakeholders in the pegfilgrastim biosimilar market to upscale their position in this landscape?

Pegfilgrastim Biosimilar Market: Research Methodology

In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the pegfilgrastim biosimilar market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the pegfilgrastim biosimilar market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the pegfilgrastim biosimilar market, and makes Fact.MR’s projections on the growth prospects of the pegfilgrastim biosimilar markets more accurate and reliable.

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Product Innovation / Development Trends

4. Market Background

    4.1. Macro-Economic Factors

    4.2. Forecast Factors - Relevance & Impact

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity Analysis

5. COVID19 Crisis Analysis

        5.1.1. Current COVID19 Statistics and Probable Future Impact

        5.1.2. COVID-19 Impact on GDP

        5.1.3. COVID-19 Impact of Pegfilgrastim Biosimilar Market

6. Market Context

    6.1. Product Development

    6.2. Product Adoption / Usage Analysis

    6.3. Regulatory Scenario

    6.4. Pipeline Assessment

7. Global Pegfilgrastim Biosimilar Market Value Analysis 2018-2019 and Forecast, 2019-2026

    7.1. Historical Market Value (US$ Mn) Analysis, 2018-2019 

    7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2026

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Pegfilgrastim Biosimilar Market Analysis 2018-2019  and Forecast 2020-2026, by Distributional Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Distributional Channel, 2018-2019 

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distributional Channel, 2020-2026

        8.3.1. Hospital pharmacies

        8.3.2. Retail pharmacies

        8.3.3. Mail-Order pharmacies

    8.4. Market Attractiveness Analysis By Distributional Channel

9. Global Pegfilgrastim Biosimilar Market Analysis 2018-2019  and Forecast 2020-2026, by Region

    9.1. Introduction

    9.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2019 

    9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2026

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. East Asia

        9.3.5. South Asia

        9.3.6. Oceania

        9.3.7. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Pegfilgrastim Biosimilar Market Analysis 2018-2019  and Forecast 2020-2026

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 

    10.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026

        10.3.1.  By Country

            10.3.1.1. U.S.

            10.3.1.2. Canada

        10.3.2. By Application

        10.3.3. By Distributional Channel

    10.4. Market Attractiveness Analysis

    10.5. Key Market Participants - Intensity Mapping

    10.6. Drivers and Restraints - Impact Analysis

11. Latin America Pegfilgrastim Biosimilar Market Analysis 2018-2019  and Forecast 2020-2026

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 

    11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026

        11.3.1.  By Country

            11.3.1.1. Brazil

            11.3.1.2. Mexico

            11.3.1.3. Argentina

            11.3.1.4. Rest of Latin America

        11.3.2. By Application

        11.3.3. By Distributional Channel

    11.4. Market Attractiveness Analysis

    11.5. Key Market Participants - Intensity Mapping

    11.6. Drivers and Restraints - Impact Analysis

12. Europe Pegfilgrastim Biosimilar Market Analysis 2018-2019  and Forecast 2020-2026

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 

    12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026

        12.3.1.  By Country

            12.3.1.1. Germany

            12.3.1.2. Italy

            12.3.1.3. France

            12.3.1.4. U.K.

            12.3.1.5. Spain

            12.3.1.6. Russia

            12.3.1.7. Rest of Europe

        12.3.2. By Application

        12.3.3. By Distributional Channel

    12.4. Market Attractiveness Analysis

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

13. South Asia Pegfilgrastim Biosimilar Market Analysis 2018-2019  and Forecast 2020-2026

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 

    13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026

        13.3.1.  By Country

            13.3.1.1. India

            13.3.1.2. Thailand

            13.3.1.3. Indonesia

            13.3.1.4. Malaysia

            13.3.1.5. Rest of South Asia

        13.3.2. By Application

        13.3.3. By Distributional Channel

    13.4. Market Attractiveness Analysis

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. East Asia Pegfilgrastim Biosimilar Market Analysis 2018-2019  and Forecast 2020-2026

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026

        14.3.1.  By Country

            14.3.1.1. China

            14.3.1.2. Japan

            14.3.1.3. South Korea

        14.3.2. By Application

        14.3.3. By Distributional Channel

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. Oceania Pegfilgrastim Biosimilar Market Analysis 2018-2019  and Forecast 2020-2026

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026

        15.3.1.  By Country

            15.3.1.1. Australia

            15.3.1.2. New Zealand

        15.3.2. By Application

        15.3.3. By Distributional Channel

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Middle East and Africa Pegfilgrastim Biosimilar Market Analysis 2018-2019  and Forecast 2020-2026

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2019 

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020-2026

        16.3.1.  By Country

            16.3.1.1. GCC Countries

            16.3.1.2. South Africa

            16.3.1.3. Rest of Middle East and Africa

        16.3.2. By Application

        16.3.3. By Distributional Channel

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Market Structure Analysis

    17.1. Market Analysis by Tier of Companies

    17.2. Market Concentration

    17.3. Market Share Analysis of Top Players

    17.4. Market Presence Analysis

        17.4.1. By Regional footprint of Players

        17.4.2. Product foot print by Players

        17.4.3. Channel Foot Print by Players

18. Competition Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Competition Deep Dive  

        18.3.1. Mylan NV

            18.3.1.1. Overview

            18.3.1.2. Product Portfolio

            18.3.1.3. Analyst Commentary 

            18.3.1.4. Key Financials

            18.3.1.5. Recent Developments

            18.3.1.6. Sales Footprint

            18.3.1.7. Strategy Overview

                18.3.1.7.1. Marketing Strategy

                18.3.1.7.2. Product Strategy

                18.3.1.7.3. Channel Strategy

        18.3.2. Novartis AG

            18.3.2.1. Overview

            18.3.2.2. Product Portfolio

            18.3.2.3. Analyst Commentary 

            18.3.2.4. Key Financials

            18.3.2.5. Recent Developments

            18.3.2.6. Sales Footprint

            18.3.2.7. Strategy Overview

                18.3.2.7.1. Marketing Strategy

                18.3.2.7.2. Product Strategy

                18.3.2.7.3. Channel Strategy

        18.3.3. Coherus BioSciences 

            18.3.3.1. Overview

            18.3.3.2. Product Portfolio

            18.3.3.3. Analyst Commentary 

            18.3.3.4. Key Financials

            18.3.3.5. Recent Developments

            18.3.3.6. Sales Footprint

            18.3.3.7. Strategy Overview

                18.3.3.7.1. Marketing Strategy

                18.3.3.7.2. Product Strategy

                18.3.3.7.3. Channel Strategy

        18.3.4. Mundipharma International 

            18.3.4.1. Overview

            18.3.4.2. Product Portfolio

            18.3.4.3. Analyst Commentary 

            18.3.4.4. Key Financials

            18.3.4.5. Recent Developments

            18.3.4.6. Sales Footprint

            18.3.4.7. Strategy Overview

                18.3.4.7.1. Marketing Strategy

                18.3.4.7.2. Product Strategy

                18.3.4.7.3. Channel Strategy

        18.3.5. Biocon

            18.3.5.1. Overview

            18.3.5.2. Product Portfolio

            18.3.5.3. Analyst Commentary 

            18.3.5.4. Key Financials

            18.3.5.5. Recent Developments

            18.3.5.6. Sales Footprint

            18.3.5.7. Strategy Overview

                18.3.5.7.1. Marketing Strategy

                18.3.5.7.2. Product Strategy

                18.3.5.7.3. Channel Strategy

        18.3.6. Intas Pharmaceuticals Ltd.

            18.3.6.1. Overview

            18.3.6.2. Product Portfolio

            18.3.6.3. Analyst Commentary 

            18.3.6.4. Key Financials

            18.3.6.5. Recent Developments

            18.3.6.6. Sales Footprint

            18.3.6.7. Strategy Overview

                18.3.6.7.1. Marketing Strategy

                18.3.6.7.2. Product Strategy

                18.3.6.7.3. Channel Strategy

        18.3.7. Pfizer Inc.

            18.3.7.1. Overview

            18.3.7.2. Product Portfolio

            18.3.7.3. Analyst Commentary 

            18.3.7.4. Key Financials

            18.3.7.5. Recent Developments

            18.3.7.6. Sales Footprint

            18.3.7.7. Strategy Overview

                18.3.7.7.1. Marketing Strategy

                18.3.7.7.2. Product Strategy

                18.3.7.7.3. Channel Strategy

        18.3.8. Dr Reddy’s Laboratories

            18.3.8.1. Overview

            18.3.8.2. Product Portfolio

            18.3.8.3. Analyst Commentary 

            18.3.8.4. Key Financials

            18.3.8.5. Recent Developments

            18.3.8.6. Sales Footprint

            18.3.8.7. Strategy Overview

                18.3.8.7.1. Marketing Strategy

                18.3.8.7.2. Product Strategy

                18.3.8.7.3. Channel Strategy

        18.3.9. Zydus Cadila

            18.3.9.1. Overview

            18.3.9.2. Product Portfolio

            18.3.9.3. Analyst Commentary 

            18.3.9.4. Key Financials

            18.3.9.5. Recent Developments

            18.3.9.6. Sales Footprint

            18.3.9.7. Strategy Overview

                18.3.9.7.1. Marketing Strategy

                18.3.9.7.2. Product Strategy

                18.3.9.7.3. Channel Strategy

        18.3.10. Apotex Inc.

            18.3.10.1. Overview

            18.3.10.2. Product Portfolio

            18.3.10.3. Analyst Commentary 

            18.3.10.4. Key Financials

            18.3.10.5. Recent Developments

            18.3.10.6. Sales Footprint

            18.3.10.7. Strategy Overview

                18.3.10.7.1. Marketing Strategy

                18.3.10.7.2. Product Strategy

                18.3.10.7.3. Channel Strategy

        18.3.11. Emcure Pharmaceuticals Pvt Ltd.

            18.3.11.1. Overview

            18.3.11.2. Product Portfolio

            18.3.11.3. Analyst Commentary 

            18.3.11.4. Key Financials

            18.3.11.5. Recent Developments

            18.3.11.6. Sales Footprint

            18.3.11.7. Strategy Overview

                18.3.11.7.1. Marketing Strategy

                18.3.11.7.2. Product Strategy

                18.3.11.7.3. Channel Strategy

        18.3.12. USV Private Limited

            18.3.12.1. Overview

            18.3.12.2. Product Portfolio

            18.3.12.3. Analyst Commentary 

            18.3.12.4. Key Financials

            18.3.12.5. Recent Developments

            18.3.12.6. Sales Footprint

            18.3.12.7. Strategy Overview

                18.3.12.7.1. Marketing Strategy

                18.3.12.7.2. Product Strategy

                18.3.12.7.3. Channel Strategy

        18.3.13. Lupin

            18.3.13.1. Overview

            18.3.13.2. Product Portfolio

            18.3.13.3. Analyst Commentary 

            18.3.13.4. Key Financials

            18.3.13.5. Recent Developments

            18.3.13.6. Sales Footprint

            18.3.13.7. Strategy Overview

                18.3.13.7.1. Marketing Strategy

                18.3.13.7.2. Product Strategy

                18.3.13.7.3. Channel Strategy

        18.3.14. Kashiv Biosciences

            18.3.14.1. Overview

            18.3.14.2. Product Portfolio

            18.3.14.3. Analyst Commentary 

            18.3.14.4. Key Financials

            18.3.14.5. Recent Developments

            18.3.14.6. Sales Footprint

            18.3.14.7. Strategy Overview

                18.3.14.7.1. Marketing Strategy

                18.3.14.7.2. Product Strategy

                18.3.14.7.3. Channel Strategy

        18.3.15. Fresenius Kabi

            18.3.15.1. Overview

            18.3.15.2. Product Portfolio

            18.3.15.3. Analyst Commentary 

            18.3.15.4. Key Financials

            18.3.15.5. Recent Developments

            18.3.15.6. Sales Footprint

            18.3.15.7. Strategy Overview

                18.3.15.7.1. Marketing Strategy

                18.3.15.7.2. Product Strategy

                18.3.15.7.3. Channel Strategy

        18.3.16. Green Cross Corp

            18.3.16.1. Overview

            18.3.16.2. Product Portfolio

            18.3.16.3. Analyst Commentary 

            18.3.16.4. Key Financials

            18.3.16.5. Recent Developments

            18.3.16.6. Sales Footprint

            18.3.16.7. Strategy Overview

                18.3.16.7.1. Marketing Strategy

                18.3.16.7.2. Product Strategy

                18.3.16.7.3. Channel Strategy

        18.3.17. Jiangsu Hengrui Medicine Co., Ltd

            18.3.17.1. Overview

            18.3.17.2. Product Portfolio

            18.3.17.3. Analyst Commentary 

            18.3.17.4. Key Financials

            18.3.17.5. Recent Developments

            18.3.17.6. Sales Footprint

            18.3.17.7. Strategy Overview

                18.3.17.7.1. Marketing Strategy

                18.3.17.7.2. Product Strategy

                18.3.17.7.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Pegfilgrastim Biosimilar Market Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2020 to 2026